Crinetics Pharmaceuticals Business Summary

Crinetics Pharmaceuticals, Inc. (CRNX) is a commercial-stage biopharmaceutical company specializing in the discovery and development of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company generates revenue primarily through product sales of its lead therapy, PALSONIFY (paltusotine), which in September 2025 became the first FDA-approved once-daily oral somatostatin receptor ligand for the treatment of acromegaly. Crinetics also derives income from strategic licensing agreements, notably with Sanwa Kagaku Kenkyuso (SKK) for the Japanese market, and maintains a robust pipeline including atumelnant for congenital adrenal hyperplasia and Cushing’s syndrome. In the competitive landscape, Crinetics directly challenges established players like Novartis, Ipsen, and Recordati Rare Diseases by offering a non-peptide oral alternative to the current standard-of-care injectable somatostatin analogs, effectively positioning itself as a market disruptor focused on reducing patient treatment burden. The company was co-founded by a team of veteran scientists from Neurocrine Biosciences, including President and CEO R. Scott Struthers, Ph.D., and Chief Scientific Officer Stephen F. Betz, Ph.D., both of whom possess extensive expertise in GPCR-targeted drug discovery. The leadership team was further strengthened by the 2025 appointments of Tobin Schilke as CFO (formerly of Revance and Genentech) and Isabel Kalofonos as Chief Commercial Officer (formerly of ImmunoGen and Takeda). Following the late 2025 resignation of the Chief Medical Officer, Jeff Knight was elevated to Chief Development and Operating Officer in January 2026 to oversee the company’s transition into a fully integrated commercial entity. Crinetics is backed by a sophisticated roster of life science investors, including Versant Ventures, 5AM Ventures, Frazier Healthcare Partners, and Perceptive Advisors, with a board of directors chaired by industry veteran Wendell Wierenga, Ph.D.